A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance

NCT07321015 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Platinum-sensitive
TNBC, Triple Negative Breast Cancer
BRCA1/2 Mutation or Not

Interventions

DRUG: Fluzoparib Monotherapy

Sponsor

Tianjin Medical University Cancer Institute and Hospital